Shukra Pharmaceuticals (524632) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
13 Aug, 2025Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2025, and reviewed business operations.
Financial highlights
Revenue from operations for Q1 FY26 was ₹539.11 lakhs, up from ₹317.80 lakhs year-over-year.
Total income for the quarter was ₹650.08 lakhs, compared to ₹389.56 lakhs in Q1 FY25.
Net profit for the quarter stood at ₹102.96 lakhs, up from ₹48.53 lakhs in the same quarter last year.
Basic and diluted EPS for the quarter were ₹0.02, compared to ₹0.11 in Q1 FY25.
Outlook and guidance
Financial statements prepared in accordance with Indian Accounting Standards and SEBI regulations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Shukra Pharmaceuticals
- Q3 FY26 revenue and profit surged, with strong audit review and MD re-appointment.524632
Q3 25/264 Feb 2026 - Q2 FY26 saw higher revenue, profit, and cash, with clean auditor review and no complaints.524632Q2 25/2613 Nov 2025
- Q2 FY2024-25 revenue grew, but net profit and EPS fell; cash reserves increased.524632Q2 24/2513 Jun 2025
- Q1 FY25 saw a significant drop in revenue and profit, but auditors raised no concerns.524632Q1 24/2513 Jun 2025
- FY25 revenue and profit declined sharply, but financial position and compliance remain strong.524632Q4 24/256 Jun 2025
- Quarterly profit and revenue surged, with strengthened audit oversight.524632Q3 24/256 Jun 2025